https://clarivate.com/life-sciences-healthcare/report/dlsfon0007-2024-biopharma-non-small-cell-lung-cancer-disease-landscape-forecast-g7-2024/
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024 | Clarivate
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors...
non small cell lung cancerg7 2024
https://clarivate.com/life-sciences-healthcare/report/dlsfcv0007-2024-biopharma-acute-coronary-syndrome-secondary-prevention-disease-landscape-forecast-g7-2024/
Acute Coronary Syndrome: Secondary Prevention | Disease Landscape & Forecast | G7 | 2024 | Clarivate
Acute coronary syndrome (ACS) encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. ACS is a...
acute coronary syndromesecondary preventiong7 2024